# Tolerability: Will Quad-Agonists Address GI Side Effects Seen with Retatrutide?

Canonical source: https://retacompare.com/research/tolerability-will-quad-agonists-solve-retatrutide-s-gi-side-effects

vs Retatrutide · 2026-05-02


    This article examines how next-generation quad-agonists, potentially incorporating amylin or Y2 components, could improve tolerability compared to the gastrointestinal side effects observed with Retatrutide, a GLP-1/GIP/glucagon triple agonist currently in Phase 3 trials.

 The big picture

The landscape of obesity and metabolic disorder treatments is evolving rapidly, particularly with the advent of multi-agonist therapies. Retatrutide (LY3437943), a GLP-1/GIP/glucagon triple agonist, is currently under investigation in Phase 3 trials. While it shows promise for weight loss and metabolic improvement, gastrointestinal (GI) side effects have been a significant concern. This has led researchers to explore the potential of quad-agonists, which may include additional mechanisms to enhance tolerability. By integrating amylin or Y2 receptor components, these next-generation therapies could mitigate some of the adverse effects seen with Retatrutide.

 How it works

Retatrutide functions by activating three key receptors: GLP-1, GIP, and glucagon. Each receptor plays a role in regulating appetite, glucose metabolism, and energy expenditure. GLP-1 agonists, like Semaglutide and Tirzepatide, have already demonstrated efficacy in weight management and glycemic control. However, the activation of glucagon can lead to increased gastric motility, contributing to GI side effects. Quad-agonists aim to add another layer of complexity by incorporating amylin or Y2 receptor agonism. Amylin, a hormone co-secreted with insulin, can promote satiety and slow gastric emptying, while Y2 receptor activation may further enhance appetite regulation, potentially leading to improved tolerability.

 Key points at a glance

Retatrutide is a GLP-1/GIP/glucagon triple agonist currently in Phase 3 trials.

GI side effects are a notable concern with Retatrutide.

Next-generation quad-agonists are being explored to enhance tolerability.

Amylin and Y2 receptor components may mitigate GI issues.

Other dual agonists, such as Tirzepatide and Mazdutide, have shown varying tolerability profiles.

No quad-agonist or penta-agonist therapies are currently approved.

Research is ongoing to better understand receptor interactions and their clinical implications.

 Where this fits in the pipeline

Quad-agonist therapies are largely in the preclinical or early clinical stages. Companies like Hanmi are developing HM15275, a quad-agonist that includes GLP-1, GIP, glucagon, and amylin pathways. Other programs, such as those from Amgen (MariTide) and Zealand Pharma (Petrelintide), are also exploring multi-agonist approaches. While specific timelines for these candidates are uncertain, early data suggests they may provide additional benefits in terms of weight loss and metabolic health. The integration of amylin or Y2 components is a promising avenue, but comprehensive clinical data is still needed.

 What it could mean for patients

If quad-agonist therapies successfully enhance tolerability, they could significantly impact patient adherence and overall treatment outcomes. Improved tolerability may lead to better long-term weight management and metabolic control, addressing a critical gap in current obesity treatments. However, it is essential to approach these possibilities cautiously, as early-stage data often does not translate directly to clinical success.

 Open questions and what we don't yet know

Several uncertainties remain regarding the development of quad-agonists. The efficacy of adding amylin or Y2 components to existing multi-agonist frameworks is still theoretical. Additionally, potential regulatory hurdles must be navigated before any new therapies can reach the market. Understanding the full spectrum of side effects, as well as the long-term safety profiles of these combinations, will be critical as research progresses.

 Bottom line

Quad-agonists may offer a pathway to improved tolerability compared to Retatrutide, but much remains to be explored in terms of clinical efficacy and safety.

 This article is research-only educational content and is not medical advice. None of the drugs discussed are approved as quad-agonists or penta-agonists at the time of writing.

## Sources